Premium
Recent development and potential use of µ‐ and κ‐opioid receptor ligands in positron emission tomography studies
Author(s) -
Henriksen Gjermund,
Willoch Frode,
Talbot Peter S.,
Wester HansJürgen
Publication year - 2006
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20161
Subject(s) - positron emission tomography , neuroscience , opioid , opiate , medicine , receptor , central nervous system , opioid receptor , pharmacology , psychology
Quantitative non‐invasive imaging of target structures in the human central nervous system provided by positron emission tomography (PET) permits investigation of the relationship between molecular events and pharmacological effects in living humans. Due to their prominent role in opiate and stimulant drug misuse and dependence, as well as in nociceptive signaling, µ‐ and κ‐opioid receptors are potential targets for advances in neuro(psycho)pharmacological treatment of these illnesses and syndromes. In this review, we describe recent developments in specific positron emitting radiopharmaceuticals for these opioid receptor subclasses. Implications for further advances and clinical applications of the labeled ligands are discussed. Drug Dev. Res. 67:890–904, 2006. © 2007 Wiley‐Liss, Inc.